Dynavax (DVAX) Tops Q2 EPS by 12c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts DVAX Hot Sheet
Price: $15.50 --0%
Financial Fact:
Loss from operations: -34.84M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Loss from operations: -34.84M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Dynavax (NASDAQ: DVAX) reported Q2 EPS of $0.03, $0.12 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $56 million versus the consensus estimate of $48.39 million.
GUIDANCE:
Dynavax sees Q3 2023 revenue of $200-215 million, versus the consensus of $193.2 million.
For earnings history and earnings-related data on Dynavax (DVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Ascendis Pharma (ASND) Tops Q2 EPS by 132c
- Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
